State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Oct. 15
State Street Health Care Select Sector SPDR ETF (XLV) added positions in Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV) on Oct. 15, with purchases totaling $48.4M, $29.5M, and $24.2M respectively. XLV's portfolio remains entirely in healthcare equities, with a 15.57% YTD return and a 1.44% dividend yield.
How this was made
The 30-second read
Why it matters
The fund’s purchases add modest buying pressure to its largest holdings, but the scale is small relative to each company’s market cap.
Market read
ETF inflows and new positions provide a modest, short‑term boost to the listed healthcare stocks mentioned.
What to watch
The fund’s overall $309.8 M inflow could benefit the broader healthcare sector beyond the top five holdings.
Background
State Street's XLV ETF recorded a net inflow of $309.8 M, increasing its exposure to top healthcare names.
Ticker impact
XLV added 38,640 shares of Eli Lilly worth $48.4 M, making it the top holding.
likely slight upward pressure as the fund adds a sizable position
ETF inflows and new purchases can support the stock but the amount is modest relative to market cap.
XLV purchased 116,410 shares of Johnson & Johnson for $29.5 M, raising its weight to 9.52%.
likely slight upward pressure as the fund adds shares
ETF buying is a positive signal but the dollar amount is small relative to JNJ’s size.
XLV added 85,365 shares of AbbVie for $24.2 M, increasing its weight to 7.81%.
likely slight upward pressure as the fund adds a position
The purchase is modest relative to ABBV’s market cap.
XLV added 43,365 shares of UnitedHealth Group for $17.6 M, raising its weight to 5.69%.
likely slight upward pressure as the fund adds shares
The dollar amount is relatively small for a large‑cap like UNH.
XLV added 119,210 shares of Merck for $17.3 M, bringing its weight to 5.59%.
likely slight upward pressure as the fund adds a position
The purchase size is modest relative to MRK’s market cap.
Market effects
Shows continued investor appetite for large‑cap healthcare stocks within the sector.
U.S. healthcare sector may see modest uplift from ETF inflows.
Limited to U.S. equity markets; no broader macro impact.
Counterpoint
ETF buying may already be priced in; the incremental impact on large‑cap stocks could be negligible.
Key entities
- ETFState Street Health Care Select Sector SPDR ETF
XLV, a sector-focused healthcare fund.
